The US Food and Drug Administration (FDA) approved expanded pediatric indication for Epclusa® (sofosbuvir/velpatasvir) to treat chronic hepatitis C virus.
The US Food and Drug Administration has approved an indication expansion in pediatrics for Epclusa® (sofosbuvir/velpatasvir), which is a treatment for chronic hepatitis C virus. The approval allows the medication from Gilead Sciences, Inc. to be used in children as young as 3 years of age, with no regard for hepatitis C virus genotype or liver disease severity. The approval was for 2 strength oral pellet formulations of Epclusa (sofosbuvir 200 mg/velpatasvir 50 mg and sofosbuvir 150 mg/velpatasvir 37.5 mg) for use in children who are not able to swallow tablets.
A Phase 2, open-label clinical trial was the basis for the approval. The trial include 41 children aged 3 years to less than 6 years who were treated with sofosbuvir/velpatasvir for 12 weeks. Following the treatment course, the medication had a sustained virologic response or cure rate of 83% among all patients; 88% in children with a hepatitis C virus genotype 1; 50% in children with hepatitis C virus genotype 2; and 100% in children with hepatitis C virus genotype 3 and hepatitis C virus genotype 4. Among the children who did not achieve cure, all discontinued the treatment 1 to 20 days following the start of treatment.
Safety was overall consistent with what was seen with adults. Vomiting was reported in 15% of the subjects and 10% of the children had product use issues. They were rated as mild.
Reference
1.Gilead Sciences, Inc. U.S. Food and Drug Administration approves new formulation of Epclusa®, expanding pediatric indication to treat children ages 3 and older with chronic hepatitis C. Published June 10, 2021. Accessed June 11, 2021. https://www.gilead.com/news-and-press/press-room/press-releases/2021/6/us-food-and-drug-administration-approves-new-formulation-of-epclusa-expanding-pediatric-indication-to-treat-children-ages-3-and-older-with-chronic
Fluoxetine helps refractory nocturnal enuresis but not for long
March 29th 2023A 12-week study in Egypt of the efficacy of fluoxetine (a selective serotonin reuptake inhibitor) in children with treatment-refractory nocturnal enuresis (NE) found that though the treatment achieved a good initial response, it was not sustainable.
Meet the Board: Vivian P. Hernandez-Trujillo, MD, FAAP, FAAAAI, FACAAI
May 20th 2022Contemporary Pediatrics sat down with one of our newest editorial advisory board members: Vivian P. Hernandez-Trujillo, MD, FAAP, FAAAAI, FACAAI to discuss what led to her career in medicine and what she thinks the future holds for pediatrics.
Are some patients predisposed to avascular necrosis after hip surgery?
March 14th 2023Although avascular necrosis (AVN) is believed to be an iatrogenic complication following treatment of developmental dysplasia of the hip, an investigation in China found 2 characteristics associated with the condition: the likelihood of AVN increases with both the grade of dislocation and of underdevelopment of the ossific nucleus.
Meet the board: Jessica L. Peck, DNP, APRN, CPNP-PC, CNE, CNL, FAANP, FAAN
April 22nd 2022In the latest episode of our podcast series, Jessica L. Peck, DNP, APRN, CPNP-PC, CNE, CNL, FAANP, FAAN shares why she got into medicine, the myths of pediatric, and what the future may hold for the specialty.